NCT05146999View on ClinicalTrials.gov

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

October 28, 2022

Study Completion Date

September 1, 2023

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

QM1114-DP

QM1114-DP

BIOLOGICAL

Placebo

Placebo

Trial Locations (9)

21030

Galderma Research Site, Hunt Valley

27517

Galderma Research Site, Chapel Hill

33146

Galderma Research Site, Coral Gables

35209

Galderma Research Site, Homewood

68144

Galderma Research Site, Omaha

77388

Galderma Research Site, Spring

78660

Galderma Research Site, Pflugerville

90266

Galderma Research Site, Manhattan Beach

92083

Galderma Research Site, Vista

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY